274 related articles for article (PubMed ID: 26839144)
21. Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer.
De Santis M; Saad F
Urology; 2016 Oct; 96():156-164. PubMed ID: 26905032
[TBL] [Abstract][Full Text] [Related]
22. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.
Kumar A; Coleman I; Morrissey C; Zhang X; True LD; Gulati R; Etzioni R; Bolouri H; Montgomery B; White T; Lucas JM; Brown LG; Dumpit RF; DeSarkar N; Higano C; Yu EY; Coleman R; Schultz N; Fang M; Lange PH; Shendure J; Vessella RL; Nelson PS
Nat Med; 2016 Apr; 22(4):369-78. PubMed ID: 26928463
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
Doshi C; Vacchio M; Attwood K; Murekeyisoni C; Mehedint DC; Badkhshan S; Azabdaftari G; Sule N; Guru KA; Mohler JL; Kauffman EC
Prostate; 2016 Jun; 76(8):715-21. PubMed ID: 26880312
[TBL] [Abstract][Full Text] [Related]
24. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
[TBL] [Abstract][Full Text] [Related]
25. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
[TBL] [Abstract][Full Text] [Related]
26. A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update.
Walz J; Epstein JI; Ganzer R; Graefen M; Guazzoni G; Kaouk J; Menon M; Mottrie A; Myers RP; Patel V; Tewari A; Villers A; Artibani W
Eur Urol; 2016 Aug; 70(2):301-11. PubMed ID: 26850969
[TBL] [Abstract][Full Text] [Related]
27. Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer.
Demark-Wahnefried W; Nix JW; Hunter GR; Rais-Bahrami S; Desmond RA; Chacko B; Morrow CD; Azrad M; Frugé AD; Tsuruta Y; Ptacek T; Tully SA; Segal R; Grizzle WE
BMC Cancer; 2016 Feb; 16():61. PubMed ID: 26850040
[TBL] [Abstract][Full Text] [Related]
28. Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation.
Graff JN; Thomas GV; Higano CS; Beer TM
Cureus; 2015 Dec; 7(12):e426. PubMed ID: 26848415
[TBL] [Abstract][Full Text] [Related]
29. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Von Hoff DD; Mita MM; Ramanathan RK; Weiss GJ; Mita AC; LoRusso PM; Burris HA; Hart LL; Low SC; Parsons DM; Zale SE; Summa JM; Youssoufian H; Sachdev JC
Clin Cancer Res; 2016 Jul; 22(13):3157-63. PubMed ID: 26847057
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Rescigno P; Lorente D; Bianchini D; Ferraldeschi R; Kolinsky MP; Sideris S; Zafeiriou Z; Sumanasuriya S; Smith AD; Mehra N; Jayaram A; Perez-Lopez R; Mateo J; Parker C; Dearnaley DP; Tunariu N; Reid A; Attard G; de Bono JS
Eur Urol; 2016 Nov; 70(5):724-731. PubMed ID: 26965561
[TBL] [Abstract][Full Text] [Related]
31. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Halabi S; Kelly WK; Ma H; Zhou H; Solomon NC; Fizazi K; Tangen CM; Rosenthal M; Petrylak DP; Hussain M; Vogelzang NJ; Thompson IM; Chi KN; de Bono J; Armstrong AJ; Eisenberger MA; Fandi A; Li S; Araujo JC; Logothetis CJ; Quinn DI; Morris MJ; Higano CS; Tannock IF; Small EJ
J Clin Oncol; 2016 May; 34(14):1652-9. PubMed ID: 26951312
[TBL] [Abstract][Full Text] [Related]
32. Sex Differences in Cardiovascular Disease Risk of Ghanaian- and Nigerian-Born West African Immigrants in the United States: The Afro-Cardiac Study.
Commodore-Mensah Y; Hill M; Allen J; Cooper LA; Blumenthal R; Agyemang C; Himmelfarb CD
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26896477
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.
Priemer DS; Montironi R; Wang L; Williamson SR; Lopez-Beltran A; Cheng L
Endocr Pathol; 2016 Jun; 27(2):123-35. PubMed ID: 26885643
[TBL] [Abstract][Full Text] [Related]
34. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
35. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
36. Successful external validation of a model to predict other cause mortality in localized prostate cancer.
Kent M; Penson DF; Albertsen PC; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Ehdaie B; Scardino PT; Vickers AJ
BMC Med; 2016 Feb; 14():25. PubMed ID: 26860993
[TBL] [Abstract][Full Text] [Related]
37. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
38. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
[TBL] [Abstract][Full Text] [Related]
39. Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study.
Vance TM; Wang Y; Su LJ; Fontham ET; Steck SE; Arab L; Bensen JT; Mohler JL; Chen MH; Chun OK
Nutr Cancer; 2016; 68(2):214-24. PubMed ID: 26847416
[TBL] [Abstract][Full Text] [Related]
40. Testosterone and Cardiovascular Disease.
Kloner RA; Carson C; Dobs A; Kopecky S; Mohler ER
J Am Coll Cardiol; 2016 Feb; 67(5):545-57. PubMed ID: 26846952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
